People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Belhaven Biopharma Inc. | — | Pharmaceuticals | Series B | $32.3M | $146.8M | 2025 |
Scott David Lyman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott David Lyman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wes Algon Wheeler | 1 | 1 |
| David Algon Neal | 1 | 1 |
| Derek Algon Winstanly | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.